Stockscreener 앱 받기
0.813
17.34%
-0.1706
시장 영업 전:
.81
-0.003
-0.37%
Shattuck Labs Inc 주식(STTK)의 최신 뉴스
Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference - TradingView
24,446 Shares in Shattuck Labs, Inc. (NASDAQ:STTK) Acquired by Virtu Financial LLC - Defense World
STTK stock plunges to 52-week low, touches $0.93 - Investing.com
Brokers Issue Forecasts for Shattuck Labs Q1 Earnings - Defense World
515,619 Shares in Shattuck Labs, Inc. (NASDAQ:STTK) Acquired by Takeda Pharmaceutical Co. Ltd. - MarketBeat
H.C. Wainwright holds Shattuck Labs stock at Neutral - Investing.com
Shattuck Labs Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
Shattuck Labs (NASDAQ:STTK) Given Neutral Rating at HC Wainwright - Defense World
Shattuck Labs’ (STTK) “Hold” Rating Reaffirmed at Needham & Company LLC - Defense World
Shattuck Labs Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Shattuck Labs Inc (STTK) Q4 2024 Earnings: EPS of -$0.37 Misses Estimate, Revenue of $0.71M Below Expectations - GuruFocus
Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights - The Manila Times
Shattuck Labs, Inc Loss At -$18.68 Mln In Q4 - Nasdaq
Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business - Bluefield Daily Telegraph
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of STTK, TLS and ASTR - ACCESS Newswire
Leerink Partnrs Forecasts Shattuck Labs FY2024 Earnings - Defense World
Brokerages Set Shattuck Labs, Inc. (NASDAQ:STTK) Target Price at $7.50 - Defense World
Shattuck Labs (NASDAQ:STTK) Upgraded at Leerink Partnrs - Defense World
Shattuck Labs (NASDAQ:STTK) Coverage Initiated by Analysts at Leerink Partners - Defense World
Leerink Partners Initiates Coverage of Shattuck Labs (STTK) with Outperform Recommendation - Nasdaq
Leerink initiates Shattuck Labs stock with Outperform, $4 target By Investing.com - Investing.com Canada
Leerink Partners Initiates Shattuck Labs at Outperform With $4 Price Target -March 17, 2025 at 07:39 am EDT - MarketScreener
Stocks Recover Some of This Week’s Losses as US Shutdown Seems Averted - TradingView
Stocks Rally as US Government Shutdown Risks Recede - TradingView
Tariff Worries Pressure Stocks - TradingView
Tariff Worries Sink Stocks - TradingView
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of STTK, RIVN and FB - ACCESS Newswire
Shattuck Labs Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
Shattuck Labs (STTK) to Release Earnings on Thursday - Defense World
CLVT, SLI & STTK: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Upcoming Class Actions Deadlines and Encourages Shareholders to Contact the Firm - ACCESS Newswire
Shattuck Labs (STTK) Projected to Post Earnings on Wednesday - MarketBeat
Shattuck Labs reports positive preclinical SL-325 data By Investing.com - Investing.com Nigeria
Shattuck Labs reports positive preclinical SL-325 data - Investing.com
Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025 - The Manila Times
Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at ... - The Bakersfield Californian
Breakthrough in IBD Treatment? Shattuck's Novel DR3 Blocker Achieves Perfect Safety Score - StockTitan
Shattuck Labs (STTK) Expected to Announce Earnings on Wednesday - Defense World
GoHealth to Announce Fourth Quarter 2024 Results on February 27, 2025 - The Manila Times
Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025 - The Manila Times
Revolutionary IBD Drug Development: Shattuck Labs Unveils Critical DR3 Antibody Results at ECCO 2025 - StockTitan
Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights - br.ADVFN.com
Anti-DR3 antibody demonstrates efficacy in the treatment of IBD - BioWorld Online
Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis Congress - The Manila Times
Skye Bioscience Announces Participation in February Conferences - The Manila Times
Shattuck Labs, Inc. to Present Novel Research on SL-325 at 2025 Crohn’s and Colitis Congress - Nasdaq
Pivotal IBD Drug Development: Shattuck Labs Reveals SL-325 Data at Major Crohn's Congress - StockTitan
JPMorgan Chase & Co. Grows Position in Shattuck Labs, Inc. (NASDAQ:STTK) - Defense World
Natera Announces National Commercial Coverage for its Fetal RhD NIPT - BioSpace
Planet Image International Leads 3 US Penny Stocks To Consider - Simply Wall St
Cresco Labs (OTCMKTS:CRLBF) Trading 2.1% Higher – What’s Next? - Defense World
Vizient Forecasts a 3.84% Rise in Pharmacy Spending - BioSpace
ImmunoMet Therapeutics Presents Updated Clinical Data from Phase 1b Study of Lixumistat in Pancreatic Cancer at ASCO-GI Meeting - BioSpace
Can ALX Break The CD47 Curse? - News & Insights
AXA (EPA:CS) Stock Price Crosses Above 200 Day Moving Average – Here’s Why - Defense World
Barclays PLC Has $189,000 Stock Holdings in Shattuck Labs, Inc. (NASDAQ:STTK) - Defense World
1.23%
1.63%
자본화:
|
볼륨(24시간):